Ovid Therapeutics (OVID) Change in Accured Expenses (2016 - 2026)

Ovid Therapeutics' Change in Accured Expenses history runs 11 years deep, the most recent figure standing at -$1.4 million for Q1 2026.

• Quarterly Change in Accured Expenses fell 140100.0% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.5 million (down 226.75% YoY) and the FY2025 annual result came in at -$1.1 million, down 98.88% from the prior year.
• Change in Accured Expenses was -$1.4 million for Q1 2026 at Ovid Therapeutics, down from $2.1 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $4.1 million in Q2 2024 and bottomed at -$3.4 million in Q2 2022.
• A 5-year average of -$244270.9 and a median of -$1000.0 in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2025 — Change in Accured Expenses jumped 229.55% — and 2026, when it plunged 140100.0%.
• Ovid Therapeutics' Change in Accured Expenses stood at -$1.2 million in 2022, then soared by 125.36% to $303000.0 in 2023, then slumped by 622.77% to -$1.6 million in 2024, then soared by 229.55% to $2.1 million in 2025, then plunged by 168.32% to -$1.4 million in 2026.
• Business Quant data shows OVID's Change in Accured Expenses at -$1.4 million in Q1 2026, $2.1 million in Q4 2025, and $27000.0 in Q3 2025.